Actuate Therapeutics receives Nasdaq notice of MVLS deficiency, has 180 days to cure
Actuate Therapeutics received a notice from Nasdaq on July 15, 2026, that its Market Value of Listed Securities (MVLS) fell below the $50 million minimum required for continued listing on The Nasdaq Global Market from June 1 to July 14, 2026. The company has 180 calendar days, through January 11, 2027, to regain compliance; if it does not, Nasdaq will issue a delisting notice, which the company may appeal or it may apply to transfer to The Nasdaq Capital Market. The company's stock continues to trade on Nasdaq under symbol "ACTU" with no immediate effect on its listing.
Key facts
- MVLS fell below $50 million minimum required for continued listing on Nasdaq Global Market from June 1, 2026 to July 14, 2026
- 180 calendar days from July 15, 2026 (notice date) to January 11, 2027 (Compliance Date) to regain compliance
- Company must achieve MVLS of $50 million or more for a minimum of ten consecutive business days to receive written confirmation of compliance
- If non-compliant by January 11, 2027, Nasdaq will issue a delisting notice; company may appeal or apply for transfer to Nasdaq Capital Market
- Stock continues trading on Nasdaq Global Market under symbol "ACTU" with no immediate delisting effect
Why it matters
The deficiency notice does not trigger immediate delisting but establishes a six-month timeline for the company to stabilize its market valuation; failure to do so will force either a successful appeal, a transfer to a lower-tier market, or delisting.
Share
Derived from 8-K filed 2026-07-17. Not investment advice. View the source filing on SEC.gov →